NKTR News

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Korsinsky

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence?

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

Form 8-K

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE) Announced by Holzer & Holzer, LLC

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders Have Opportunity to Lead Class Action Lawsuit!

Class Action Filed by Pomerantz LLP Against Nektar Therapeutics – NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Pomerantz LLP Pursues Class Action Lawsuit Against Nektar Therapeutics – NKTR